- Home
- IMCR vs RNW Comparison
IMCR vs RNW Comparison
Compare IMCR & RNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- RNW
- Stock Information
- Founded
- IMCR 2008
- RNW 2011
- Country
- IMCR United Kingdom
- RNW United Kingdom
- Employees
- IMCR N/A
- RNW N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- RNW Electric Utilities: Central
- Sector
- IMCR Health Care
- RNW Utilities
- Exchange
- IMCR Nasdaq
- RNW Nasdaq
- Market Cap
- IMCR 1.6B
- RNW 2.4B
- IPO Year
- IMCR 2021
- RNW N/A
- Fundamental
- Price
- IMCR $33.99
- RNW $7.52
- Analyst Decision
- IMCR Buy
- RNW Strong Buy
- Analyst Count
- IMCR 10
- RNW 1
- Target Price
- IMCR $58.13
- RNW $7.50
- AVG Volume (30 Days)
- IMCR 422.6K
- RNW 1.3M
- Earning Date
- IMCR 08-07-2025
- RNW 08-14-2025
- Dividend Yield
- IMCR N/A
- RNW N/A
- EPS Growth
- IMCR N/A
- RNW 16.07
- EPS
- IMCR N/A
- RNW 0.13
- Revenue
- IMCR $333,581,000.00
- RNW $1,135,947,896.00
- Revenue This Year
- IMCR $26.82
- RNW N/A
- Revenue Next Year
- IMCR $8.15
- RNW $17.72
- P/E Ratio
- IMCR N/A
- RNW $59.09
- Revenue Growth
- IMCR 25.75
- RNW 19.36
- 52 Week Low
- IMCR $23.15
- RNW $5.15
- 52 Week High
- IMCR $41.54
- RNW $7.67
- Technical
- Relative Strength Index (RSI)
- IMCR 56.49
- RNW 65.54
- Support Level
- IMCR $32.20
- RNW $7.41
- Resistance Level
- IMCR $33.95
- RNW $6.94
- Average True Range (ATR)
- IMCR 1.22
- RNW 0.18
- MACD
- IMCR 0.06
- RNW 0.08
- Stochastic Oscillator
- IMCR 95.84
- RNW 87.50
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About RNW ReNew Energy Global plc
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.